Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).

被引：0
|
作者：
Ruff, P [1 ]
Moodley, SD [1 ]
Rapoport, BL [1 ]
Chasen, MR [1 ]
Jacobs, C [1 ]
Hacking, D [1 ]
Voroblof, DA [1 ]
机构：
[1] S African Caelyx Investigators Grp, Johannesburg, South Africa
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306P
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [31] Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
    Jehn, Christian F.
    Hemmati, Philipp
    Lehenbauer-Dehm, Silvia
    Kuemmel, Sherko
    Flath, Bernd
    Schmid, Peter
    CLINICAL BREAST CANCER, 2016, 16 (06) : 514 - 519
  • [32] Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
    Caponigro, F
    Comella, P
    Budillon, A
    Bryce, J
    Avallone, A
    De Rosa, V
    Ionna, F
    Comella, G
    ANNALS OF ONCOLOGY, 2000, 11 (03) : 339 - 342
  • [33] Phase II pilot study of caelyx (doxorubicin HCL, pegylated liposomal) in patients with inoperable squamous cell cancer of the head and neck
    Stewart, JSW
    Harrington, KJ
    Harrison, D
    Whittaker, J
    Elliott, P
    ANNALS OF ONCOLOGY, 1998, 9 : 170 - 170
  • [34] Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in the treatment of advanced hepatocellular carcinoma (HCC)
    Pastorelli, D.
    Zustovich, F.
    Lombardi, G.
    Zovato, S.
    Farina, M.
    Furini, L.
    Faggioni, G.
    Nicoletto, M. O.
    Ceravolo, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 396
  • [35] A phase II study evaluating the tolerability and efficacy of CAELYX (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma
    Halford, S
    Yip, D
    Karapetis, CS
    Strickland, AH
    Steger, A
    Khawaja, HT
    Harper, PG
    ANNALS OF ONCOLOGY, 2001, 12 (10) : 1399 - 1402
  • [36] Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent head and neck cancer (HN).
    Caponigro, F
    Avallone, A
    Rivellini, F
    Budillon, A
    Di Gennaro, E
    Ionna, F
    Mozzillo, N
    Marcolin, P
    Comella, P
    Comella, G
    CLINICAL CANCER RESEARCH, 1999, 5 : 3819S - 3819S
  • [37] A phase IV study of neo-adjuvant combination chemotherapy with pegylated liposomal doxorubicin (CAELYX®) and vinorelbine for locally advanced breast cancer
    Shen, Z. Z.
    Shao, M. Z.
    Xu, H. B.
    Wang, L.
    Wang, S. Y.
    Liu, J.
    He, Q. P.
    Su, X. F.
    Jiang, F. Z.
    Zhang, B.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S230 - S230
  • [38] Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study
    Di Lorenzo, Giuseppe
    Rea, Antonio
    Carlomagno, Chiara
    Pepe, Stefano
    Palmieri, Giovannella
    Labianca, Roberto
    Chirianni, Antonio
    De Stefano, Alfonso
    Esposito, Vincenzo
    De Placido, Sabino
    Montesarchio, Vincenzo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (48) : 6553 - 6557
  • [39] Locoregional effects of pegylated liposomal doxorubicin (Caelyx®) in irradiated area:: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck
    Faivre, S
    Alsabe, H
    Djafari, L
    Janot, F
    Julieron, M
    Domenge, C
    Djazouli, K
    Armand, JP
    Luboinski, B
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (10) : 1517 - 1521
  • [40] Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study
    Leonardi, Vita
    Palmisano, Valentina
    Pepe, Alessio
    Usset, Antonella
    Manuguerra, Giovanna
    Savio, Giuseppina
    De Bella, Manuela Tamburo
    Laudani, Agata
    Alu, Massimo
    Cusimano, Maria Pia
    Scianna, Caterina
    Giresi, Armando
    Agostara, Biagio
    ONCOLOGY LETTERS, 2010, 1 (04) : 749 - 753
12345